Merck and Sanofi have become the latest pharmaceutical companies to participate in the TrumpRx.gov website, which offers prescription medication discounts under the 'most-favored-nation' pricing initiative. Merck added three popular Type 2 diabetes medications—Januvia, Janumet, and Janumet XR—reducing their cost by 74% to $84.57 from $330. This marks Merck as the 12th company to join the program. Sanofi, now the 13th company to offer discounts, is listing diabetes, tuberculosis, and blood medications. Sanofi's most expensive addition, Toujeo, will see its price cut by 92%, costing $35 instead of $428.57 through TrumpRx.gov [1].
The Trump administration is enforcing 100% tariffs on imported, branded, and patented pharmaceutical products, but these tariffs are waived for companies that agree to the most-favored-nation drug pricing deals. President Donald Trump stated that pharmaceutical companies agreed to participate because of the tariffs [1].
Recent market data shows Merck's stock (MRK) closed at $120.15, down 1.05%, while Sanofi's stock (SNY) rose 0.43% to $46.96. Additionally, Bristol Myers Squibb added three medications to the government website in late March [1].
Prescription drug prices fell 1.5% in March on a monthly basis, according to the Bureau of Labor Statistics' latest consumer price index data. Prices declined 0.2% from one year ago, indicating a broader trend of decreasing drug costs potentially influenced by these initiatives [1].
CONCLUSION
Merck and Sanofi's participation in the TrumpRx discount program marks a significant step in reducing prescription drug prices, with substantial price cuts on key medications. The move is part of a broader government effort leveraging tariffs to encourage pharmaceutical companies to offer lower prices. Early market reactions are mixed, but the overall trend points toward lower drug costs for consumers.